

SUB H1
cont

NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13),
GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15),
QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRG (SEQ ID NO:17),
SGGRGRGG (SEQ ID NO:18), RGGSGRRGRGR (SEQ ID NO:19),
RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21),
RPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23),
PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID
NO:26), DGGRRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGGSN (SEQ ID NO:28),
GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31),
VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID
NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ
ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations thereof, wherein the peptide
comprises up to about forty amino acids and is present either in free form or bound to a carrier
molecule.

28. (twice amended) A method comprising administering to an individual a peptide
composition comprising a molecule selected from the group consisting of PPPGRRP (SEQ ID
NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3),
GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7),
GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP
(SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16),

61

SUB H1
GTGAGAGARGRG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR
(SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID
NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID
NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ
ID NO:26), , GKHRGQGGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA
(SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32),
GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35),
CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ ID NO:37), PPWFPPMVEG (SEQ ID
NO:38), and combinations or immunogenic portions thereof, wherein the peptide comprises up
to about forty amino acids and is present either in free form or bound to a carrier molecule, and
wherein the composition is in a pharmaceutically acceptable carrier for administration of the
composition in an amount and mode of administration effective to induce tolerance to EBV-
associated immune responses.

G1
G2

29. (amended) The [immunogenic] composition of claim 27 wherein the peptide
molecules are in a pharmaceutically acceptable carrier for administration of the composition in
an amount and mode of administration effective to induce tolerance to EBV-associated immune
responses wherein the composition is in a pharmaceutically acceptable carrier for administration
of the composition in an amount and mode of administration effective to induce tolerance to
EBV-associated immune responses.

35. (amended) A method for determining the likelihood that an individual has or will develop an autoimmune disorder comprising screening their antibodies for reactivity with a peptide molecule selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGS GSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRG (SEQ ID NO:17), SGGRRGG (SEQ ID NO:18), RGGSGRRGRGR (SEQ ID NO:19), RARGRRGRGEGKRRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21), RPPPGRPPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), PGAIEQGPA (SEQ ID NO:24), GRSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID NO:26), DGGRRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQPGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations or immunogenic portions thereof, wherein the peptide comprises up to about forty amino acids and is present either in free form or bound to a carrier molecule.